Astrazeneca Plc · LSE:AZN
Astrazeneca — Investor Day (March 2021)
13 slides from Astrazeneca's investor day presentation, Mar 25, 2021
Slide 1: Respiratory & Immunology: emerging pipeline
Break-out session 3 Respiratory & Immunology: emerging pipeline Maria Belvisi, Senior Vice President, early-stage R&D Ben Fenby, Global Franchise Head, inhaled medicines, BioPharmaceuticals Business Unit Iain Chessell, Head of Neuroscience, early-stage R&D 25 March 2021 Interactive event for investo
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ’the Group’) provides the following cautionary statement: this document contains certain forward-looking statements wit
Slide 3: Targeting diseases with great unmet medical need
Targeting diseases with great unmet medical need Building on 50 years of respiratory care in immune-driven diseases COPD 1 Immunology Asthma COPD4 Immunology >50% 3rd 5-7% leading cause of of people living with autoimmune patients remain death worldwide5,6 uncontrolled1 diseases, ranging from ultra-
Slide 4: Respiratory & Immunology: strategy
Respiratory & Immunology: strategy Disease modification and clinical remission Diseases with great unmet need Increased probability of success Transformative endpoints Asthma COPD IPF1 Cough Differentiated and New modalities - unbiased novel nothing is Demonstrating disease modification: targets und
Slide 5: MEDI3506: IL33 mAb targeting a damage-response epithelial cytokine
MEDI3506: IL331 mAb2 Targeting a broad-acting, damage-response epithelial cytokine Disease-modification potential Reverting the epithelial phenotype Damage COPD + control mAb COPD + MEDI3506 OX-IL333 RED-IL334 X X Ciliated: alpha-tubulin; goblet: mucin 5AC/5B; basal: P63 Non-ST25 100 muc5ac mRNA Pat
Slide 6: MEDI3506: IL33 mAb
MEDI3506: IL33 mAb Targeting a broad-acting, damage-response epithelial cytokine Phase I: pharmacodynamic Phase II trials effects demonstrated in COPD1 COPD Phase II n=322 FPCD4: Q1 2021 Data anticipated: 2022 Serum Asthma Phase II n=228 FPCD: Q4 2020 IL52 Data anticipated: 2022 reduction Atopic der
Slide 7: AZD1402: IL4Ra and AZD0449: iJAK
AZD14021: IL4Ra2 and AZD0449: iJAK3 Addressing unmet need in asthma Targeted approach following Inhaled targeted biologics and Opportunity for broader efficacy precedented systemic biologic inhaled broader spectrum small across asthma endotypes molecules AZD1402 AZD0449 FeNO4, a biomarker of type-2
Slide 8: MEDI7352: bispecific fusion protein specific for NGF and TNF
MEDI7352: bispecific fusion protein specific for NGF1 and TNF2 Potential synergy between blocking NGF and TNF in pain Decreased daily pain scores Modelling suggests significant Phase I/II trials in osteoarthritis patients efficacy at <50% NGF suppression 0 Treatment effect (difference from oxycodone
Slide 9: Full pipeline and news flow
Full pipeline and news flow Upcoming milestones and expanding pipeline Respiratory & Immunology: [pipeline] emerging pipeline Upcoming milestones Key news flow Phase I Phase II H1 2021 • MEDI3506 - multiple indications: AZD0284 MEDI0618 AZD14027 MEDI3506 RORg1 PAR24 antagonist mAb inhaled IL4Ra IL33
Slide 10: Questions & Answers
Questions & Answers To ask a question Webinar Click ’Raise Hand’ (preferred): or type your question into the Q&A box (alternative) Phone *6 - Toggle mute/unmute *9 - Raise hand 10
Slide 11: Appendix
Appendix 11
Slide 12: Publications
Publications MEDI3506 Trial Congress/journal Title Author Citation Pre-clinical British Thoracic Society (BTS) The pharma perspective – what can academia do (and do we need any new drugs)? Belvisi, M.G. Available at: Winter Meeting 2021 https://btswinter.online- event.co/login Pre-clinical Keystone
Slide 13: Use of AstraZeneca conference call, webcast and presentation slides
Use of AstraZeneca conference call, webcast and presentation slides The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make availabl